中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (3): 217-224.doi: 10.3969/j.issn.1007-3969.2014.03.011

• 论著 • 上一篇    下一篇

血浆miR-221在小细胞肺癌患者血浆中的表达及其临床意义

冯丽萍,罗亮,苏文媚   

  1. 广东医学院附属医院肿瘤中心肿瘤3 区,广东 湛江 524000
  • 出版日期:2014-03-31 发布日期:2014-04-01
  • 通信作者: 冯丽萍 E-mail:6985626@qq.com

The expression and clinical significance of miR-221 in plasma of patients with small cell lung cancer

FENG Li-ping, LUO Liang, SU Wen-mei   

  1. the Third Branch of Cancer Center, the Affiliated Hospital of Guangdong Medical College, Zhanjiang Guangdong 524000, China
  • Published:2014-03-31 Online:2014-04-01
  • Contact: FENG Li-ping E-mail: 6985626@qq.com

摘要:

背景与目的:MicroRNAs(miRNAs,miR)与肿瘤的发生、发展和转移密切相关。肿瘤组织中miRNAs表达水平的变化可能会引起循环miRNAs随之改变。本研究目的是探讨小细胞肺癌(small cell lungcancerSCLC)患者临床标本中miR-221的表达及其临床意义。分析miR-22151SCLC患者及20例健康对照者血浆和组织中的表达及其与各临床病理参数的关系。方法:采用实时荧光定量PCR法检测51SCLC患者癌组织、癌旁及正常组织中miR-221的表达。进一步检测血浆miR-22151SCLC患者及20例健康对照者中的表达。结合临床资料分析其表达在临床中的作用和意义,判定血浆miR-221能否作为SCLC早期诊断、治疗及预后的标志。结果:miR-221SCLC组织中的表达水平较癌旁及正常肺组织高;血浆miR-221SCLC患者中的表达较健康对照者高(P0.05)miR-221的表达与患者的性别、年龄无关(P0.05),与疾病分期、对化疗的敏感性及生存期密切相关,差异具有统计学意义(P0.05)Cox回归分析发现疾病分期、miR-221的表达可作为独立的预后因子。结论:血浆miR-221的表达与SCLC的肿瘤分期、对化疗的敏感性和生存期相关。检测血浆miR-221可作为评估SCLC患者临床预后的靶基因。

关键词: 小细胞肺癌, 实时荧光定量PCR, 血浆miR-221

Abstract:

Background and purpose: MicroRNAs (miRNAs, miR) are directly involved in cancer initiation, progression and metastasis. Alterations of miRNAs expression in cancer tissue may be reflected in circulation. We attempted to investigate the expression and clinical significance of plasma miR-221 in patients with small cell lung cancer (SCLC). The plasma and tissues levels of miR-221 in 51 SCLC patients and 20 controls were evaluated and compared among various clinicopathological characteristics. Methods: Confirmation of higher miR-221 levels in primary SCLC tissues than normal lung tissues. Evaluation of plasma miR-221 concentrations by comparing results from 51 consecutive SCLC patients and 20 healthy volunteers. Evaluation of the assay for monitoring tumour dynamics in SCLC patients. Results: Expression of miR-221 was significantly higher in SCLC tissues than in para-carcinoma tissues and normal lung tissues. Plasma miR-221 concentrations were significantly higher in SCLC patients than those in normal people (P<0.05). The expression of plasma miR-221 was not associated with gender, and age (P>0.05), correlated with significantly chemosensitivity, overall survival and clinical stage (P<0.05). Cox regression analysis indicated that plasma miR-221 expression and disease stage were found to be significantly independent prognostic factors for the SCLC patients. Conclusion: Plasma miR-221 could be a useful biomarker for cancer detection, monitoring tumour dynamics and predicting malignant outcomes in SCLC patients, and may contribute to clinical decision making in treatments.

Key words: Small cell lung cancer, QRT-PCR, Circulating miR-221